Compare VYGR & AP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | AP |
|---|---|---|
| Founded | 2013 | 1929 |
| Country | United States | United States |
| Employees | N/A | 1432 |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 198.2M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | AP |
|---|---|---|
| Price | $3.85 | $10.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 488.9K | 131.9K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $1.75 |
| 52 Week High | $5.55 | $11.11 |
| Indicator | VYGR | AP |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 61.38 |
| Support Level | $3.72 | $2.18 |
| Resistance Level | $4.31 | $11.11 |
| Average True Range (ATR) | 0.16 | 0.72 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 31.91 | 71.49 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Ampco-Pittsburgh Corp manufactures and sells engineered, high-performance specialty metal products and customized equipment utilized by industry throughout the world. It operates in two business segments, namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, & other metals. The Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, & Buffalo Pumps. The company generates a majority of its revenue from the Forged & Cast Engineered Products segment. It has a business presence in the United States & other countries.